Similar articles

• FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation.

  Woodle ES, Bruce DS, Josephson M, Newell KA, Piper JB, Millis JM, Cronin D, Whitman G, Ruebe M, Thistlethwaite JR Jr. Woodle ES, et al. Clin Transplant. 1996 Aug;10(4):323-32. Clin Transplant. 1996. PMID: 8884103 Clinical Trial.
• Use of Prograf (FK 506) as rescue therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group.

  Klintmalm GB, Goldstein R, Gonwa T, Wiesner RH, Krom RA, Shaw BW Jr, Stratta R, Ascher NL, Roberts JW, Lake J, et al. Klintmalm GB, et al. Transplant Proc. 1993 Feb;25(1 Pt 1):679-88. Transplant Proc. 1993. PMID: 7679840 Clinical Trial.
• Sirolimus as primary immunosuppressant for calcineurin inhibitor-related renal insufficiency after liver transplantation.

  Yang YJ, Li LX, He Q, Fan H, Jin ZK, Lang R, Kou JT, Li P, Xie DH, Chen DZ. Yang YJ, et al. Hepatobiliary Pancreat Dis Int. 2007 Aug;6(4):376-8. Hepatobiliary Pancreat Dis Int. 2007. PMID: 17690032
• Renal function in pediatric liver transplant patients.

  McDiarmid SV. McDiarmid SV. Kidney Int Suppl. 1996 Jan;53:S77-84. Kidney Int Suppl. 1996. PMID: 8770996 Review.
• Impact of pretransplant renal failure: when is listing for kidney-liver indicated?

  Davis CL. Davis CL. Liver Transpl. 2005 Nov;(11 Suppl 2):S35-44. doi: 10.1002/lt.20617. Liver Transpl. 2005. PMID: 16237696 Review.